De Cristofaro, Raimondo
 Distribuzione geografica
Continente #
EU - Europa 3.985
NA - Nord America 3.695
AS - Asia 1.383
SA - Sud America 34
AF - Africa 28
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 8
Totale 9.144
Nazione #
US - Stati Uniti d'America 3.662
DE - Germania 1.343
SE - Svezia 802
CN - Cina 626
UA - Ucraina 455
IT - Italia 355
SG - Singapore 327
IE - Irlanda 229
FR - Francia 189
GB - Regno Unito 153
ID - Indonesia 147
IN - India 131
FI - Finlandia 128
PL - Polonia 120
RU - Federazione Russa 96
TR - Turchia 38
HK - Hong Kong 31
CA - Canada 26
BR - Brasile 24
BE - Belgio 23
IR - Iran 21
JP - Giappone 20
NL - Olanda 20
RO - Romania 11
AU - Australia 10
CI - Costa d'Avorio 10
AT - Austria 9
KR - Corea 9
CZ - Repubblica Ceca 8
VN - Vietnam 8
CH - Svizzera 7
EG - Egitto 6
LT - Lituania 6
MK - Macedonia 6
ES - Italia 5
EU - Europa 4
ZA - Sudafrica 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AR - Argentina 3
BD - Bangladesh 3
IL - Israele 3
IQ - Iraq 3
LU - Lussemburgo 3
LV - Lettonia 3
NO - Norvegia 3
TN - Tunisia 3
AL - Albania 2
DZ - Algeria 2
GR - Grecia 2
HU - Ungheria 2
KW - Kuwait 2
MX - Messico 2
OM - Oman 2
PA - Panama 2
PE - Perù 2
PR - Porto Rico 2
TH - Thailandia 2
VE - Venezuela 2
A1 - Anonimo 1
AM - Armenia 1
BG - Bulgaria 1
BO - Bolivia 1
CL - Cile 1
DK - Danimarca 1
EC - Ecuador 1
HR - Croazia 1
MA - Marocco 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PK - Pakistan 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SA - Arabia Saudita 1
SC - Seychelles 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 9.144
Città #
Chandler 657
Ashburn 369
Jacksonville 248
Singapore 247
Dublin 221
San Mateo 212
Nanjing 159
Jakarta 143
Wilmington 138
Ann Arbor 112
Warsaw 104
Woodbridge 98
Dearborn 88
New York 88
Boston 87
Milan 84
Fairfield 77
Moscow 75
Houston 72
Lawrence 71
Redwood City 71
Pune 70
Nürnberg 65
Seattle 62
Beijing 58
Princeton 55
Cattolica 53
Nanchang 52
Marseille 45
Redmond 44
Los Angeles 42
Chicago 38
Helsinki 37
Izmir 34
University Park 33
Bremen 32
Munich 32
Hangzhou 30
Rome 30
Kunming 27
Mountain View 25
Hong Kong 24
Augusta 23
Changsha 22
Norwalk 22
Boardman 21
Shenyang 21
Brussels 20
Detroit 18
London 18
Zhengzhou 18
Bareggio 17
Hebei 17
Jiaxing 16
Shanghai 16
Tianjin 16
Cambridge 15
Kraków 14
Padova 13
Leawood 12
Chengdu 11
Hefei 11
Paris 11
Abidjan 10
Andover 10
Guangzhou 10
Hounslow 10
Lanzhou 10
Southend 10
Fremont 9
Jinan 9
Nuremberg 9
San Diego 8
Falkenstein 7
Lancaster 7
Toronto 7
Ardabil 6
Frankfurt am Main 6
Phoenix 6
Prilep 6
Seoul 6
Vienna 6
Zurich 6
Busto Arsizio 5
Edinburgh 5
Kish 5
Menlo Park 5
Ningbo 5
Ottawa 5
San Francisco 5
Simi Valley 5
Tokyo 5
Washington 5
Brno 4
Changchun 4
Dong Ket 4
Falls Church 4
Forest City 4
Gurgaon 4
Hanoi 4
Totale 4.897
Nome #
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment 279
The oxidative modification of von Willebrand factor is associated with thrombotic angiopathies in diabetes mellitus. 271
Qualitative and quantitative modifications of von willebrand factor in patients with essential thrombocythemia and controlled platelet count 271
Pathogenesis Of Portal Vein Thrombosis In Liver Cirrhosis: The Role of the ADAMTS13/VWF Unbalance 233
Novel path to IL-6 trans-signaling through thrombin-induced soluble IL-6 receptor release by platelets 152
Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development 133
Glycaemic variability affects ischaemia-induced angiogenesis in diabetic mice. 129
The Type 2b P.R1306w Natural Mutation Of Von Willebrand Factor Dramatically Enhances The Multimer Sensitivity To Shear Stress 125
Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors 123
Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13. A new prothrombotic mechanism associated with oxidative stress 120
An old drug for a new application: carbazochrome-sodium-sulfonate in HHT 108
Effect of fibrinogen concentration on the velocity of platelet aggregation. 107
Pseudo-acquired vWD in essential thrombocythemia: the role of platelets 107
Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells 106
The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. A clinical, biochemical and in silico study 104
Evaluation of the thiobarbituric acid test (TBA test) properties for the determination of glycosylated hemoglobins by comparison with chromatography and isoelectrofocusing. 102
Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from adamts-13 101
Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusion-body myopathy muscle 99
β2-Glycoprotein I Binds Thrombin and Selectively Inhibits the Enzyme Procoagulant Functions 98
Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study 94
Congenital prothrombin deficiency: an update 93
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 91
Kinetic study of von Willebrand factor self-aggregation induced by ristocetin 90
Structural and funtional mapping of the thrombin domain involved in the binding to the platelet glycoprotein Ib 89
Increased platelet-fibrinogen affinity in patients with myeloproliferative disorders. 82
Hexopeptidase high performance liquid chromatography (HPLC) mapping and is application to peptide sequence strategies. 82
Aims: The ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation (ORIGAMI) study investigates the safety and efficacy of Edoxaban administered via PEG in patients with atrial fibrillation and a clinical indication for a long-term anticoagulation. Design: In this prospective, single-centre observational study, 12 PEG-treated patients with indication to anticoagulation will receive edoxaban via PEG and will be followed up to 6 months. Plasma antifactor Xa activity and edoxaban concentrations will be assessed. Thromboembolic (ischaemic stroke, systemic embolism, venous thromboembolism) and bleeding events (Bleeding Academic Research Consortium and Thrombolysis in Myocardial Infarction) will be recorded at 1 and 6 months. Preliminary results: A retrospective analysis of five atrial fibrillation cases undergoing PEG implantation at our Institution who received edoxaban via PEG showed plasma anti-FXa levels at a steady state of 146 ± 15 ng/ml, without major adverse event at a mean follow-up of 6 months. Conclusion: ORIGAMI prospectively investigates PEG-administration of edoxaban in PEG-treated patients requiring long-term anticoagulation. Our preliminary retrospective data support this route of DOAC administration. 82
PURIFICATION OF THE ISOLATED BETA-CHAIN OF ADULT HUMAN-HEMOGLOBIN FROM ITS POST-TRANSLATIONAL MODIFICATION 81
high performance liquid chromatography in protein sequence determination. 79
Defective platelet responsiveness to thrombin and protease-activated receptors agonists in a novel case of gray platelet syndrome: correlation between the platelet defect and the alpha-granule content in the patient and four relatives 79
Direct oral anticoagulants and therapeutic adherence: do not let your guard down 77
Homocysteinemia is inversely correlated with platelet count and inversely correlated with sE-and sP-selectin levels in females homozygous for C677T methylenetetrahydrofolate reductase 75
Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. 75
Biochemical properties of indoleamine 2,3-dioxygenase: from structure to optimized design of inhibitors 74
Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects 74
Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. 73
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 72
Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban 72
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 72
Immune toilerance by intermittent factor VIII boluses in two hemophilia A patients 71
SPONTANEOUS DEEP HEMATOMAS IN 2 PATIENTS WITH MYELOFIBROSIS - EVIDENCE OF PLATELET MEMBRANE GLYCOPROTEIN MODIFICATIONS 71
Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects. 71
Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy 71
Hemophilia A and von Willebrand deficiency: therapeutic implications 71
Does chronic oral anticoagulation reduce in-hospital mortality among COVID-19 older patients? 71
Detection of Platelet-Activating Antibodies Associated with Vaccine-Induced Thrombotic Thrombocytopenia by Flow Cytometry: An Italian Experience 71
The effect of shear stress on protein conformation: Physical forces operating on biochemical systems: The case of von Willebrand factor. 70
Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma 70
Another family with IGPS 69
Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response 69
Diagnosis and management of cerebral venous sinus thrombosis in children: a single-center retrospective analysis 69
Placental-derived PGI2 inhibits cord blood platelet function 68
Allosteric equilibria in the binding reaction of fibrinogen to platelets. 68
Proteolytic Processing of Von Willebrand Factor by Adamts13 and Leukocyte Proteases 68
Inherited macrothrombocytopenia with distinctive platelet ultrastructural and functional features 67
Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy 67
Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D9D3 and D4 domains 67
Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma 66
β2 -Glycoprotein I binds to thrombin and selectively inhibits the enzyme procoagulant functions 66
Thrombin-thrombomodulin interaction: energetics and potential role of water as an allosteric effector. 64
Placental derived PGI2 inhibits cord platelet function:possible role of PGI in THR transient hyporeactivity of newborn platelets 64
Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients 63
Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter 63
From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19 63
The dominant-negative von Willebrand factor gene deletion p.P1127_C1948delinsR: molecular mechanism and modulation. 62
Congenital prothrombin deficiency 62
The expanding spectrum of PRPS1-associated phenotypes: three novel mutations segregating with X-linked hearing loss and mild peripheral neuropathy 62
High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism 61
A recurrent Gly43Asp substitution in coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking 61
MORE EARLY BLEEDS ASSOCIATED WITH HIGH BASELINE DIRECT ORAL ANTICOAGULANT LEVELS IN ATRIAL FIBRILLATION: THE MAS STUDY 60
Plasma protein oxidation is associated with an increase of procoagulant markers causing an imbalance between pro- and anticoagulant pathways in healthy subjects 60
Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey 60
Ristocetin-induced self-aggregation of von Willebrand factor. 59
Binding of human alpha-thrombin to platelet GpIb: energetics and functional effects. 59
Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation 59
Apixaban Interacts with Haemoglobin: Effects on Its Plasma Levels 58
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients 57
Mechanistic studies on ADAMTS13 catalysis. 57
Wiskott-Aldrich syndrome: report of an autosomal dominant variant 57
The linkage between binding of the C-terminal domain of hirudin and amidase activity in human alpha-thrombin 56
INHIBITION OF FIBRINOGEN BINDING TO HUMAN-PLATELETS BY BLOCKAGE OF NA+/H+ EXCHANGE. 56
Carbon monoxyde and oxygen binding to human hemoglobin F0. 56
Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter 56
Mechanochemistry of von Willebrand factor 56
Thrombin interaction with platelet GpIB: role of the heparin binding domain. 55
Allosteric modulation of BPTI interaction with human alpha- and zeta-thrombin. 53
Fibrinogen-elongated gamma chain inhibits thrombin-induced platelet response, hindering the interaction with different receptors 53
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 51
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy 51
Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. 47
Measurement of plasma fibrinogen concentration by the prothrombin-time-derived method: applicability and limitations. 47
Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini‐Delphi Consensus 47
Mechanistic studies on ADAMTS13 catalysis 46
Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia 46
KINETIC ASPECTS OF RELEASE OF FIBRINOPEPTIDES AP AND AY BY HUMAN ALPHA-THROMBIN 45
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy 45
Fibrinogen-elongated gamma chain inhibits thrombin-induced platelet response, hindering the interaction with different receptors 44
Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration? 44
The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms 43
Molecular dynamics characterization of five pathogenic Factor X mutants associated with decreased catalytic activity 42
Totale 8.005
Categoria #
all - tutte 45.363
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.363


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020424 0 0 0 0 0 0 0 34 79 71 133 107
2020/2021995 36 112 27 100 150 50 109 19 117 76 166 33
2021/20221.124 83 114 24 62 64 35 34 173 60 54 206 215
2022/20231.973 264 318 165 259 155 233 80 171 230 26 56 16
2023/20241.163 41 316 30 78 49 203 66 61 17 39 102 161
2024/2025800 58 42 197 98 191 89 59 66 0 0 0 0
Totale 9.255